The age of precision medicine in cancer care for adults is rapidly approaching as it’s not uncommon now to select a treatment that’s actually tailored to each person’s unique tumor characteristics (biomarkers) as well as genetic changes in their specific cancer. For children, unfortunately the situation hasn’t progressed as fast due to a variety of reasons including a dearth of data. Now, in an effort to change that and work to bring precision cancer care to children, the University of Chicago Pediatric Cancer Data Commons (PCDC) has teamed up in a new global initiative known as The Leukemia & Lymphoma Society’s LLS PedAL (Pediatric Acute Leukemia) precision medicine master clinical trial, aiming to progress the treatment of all children with pediatric acute leukemia, including myeloid leukemia and other high-risk leukemias.
LLS PedAL will test targeted therapies for relapsed acute leukemia based on the specific genetic abnormalities driving the cancer. Leaders in childhood leukemia built the foundation for this integrated, multitherapy trial. Over 200 sites worldwide are planning on participating in this important effort.
Gwen Nichols, ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).